(NASDAQ: GPCR) Structure Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 250.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.93%.
Structure Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast GPCR's revenue for 2025 to be $27,958,824,800, with the lowest GPCR revenue forecast at $27,958,824,800, and the highest GPCR revenue forecast at $27,958,824,800. On average, 4 Wall Street analysts forecast GPCR's revenue for 2029 to be $66,791,535,535, with the lowest GPCR revenue forecast at $2,054,973,623, and the highest GPCR revenue forecast at $231,792,637,004.
In 2030, GPCR is forecast to generate $139,085,787,174 in revenue, with the lowest revenue forecast at $14,790,218,319 and the highest revenue forecast at $354,632,529,646.